GlobeNewsWire
15 Jul 2026, 17:53 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Grail announced on February 19, 2026, that the primary endpoint of a statistically significant Stage III-IV cancer reduction was not observed in the NHS-Galleri Trial. — Failure to meet the primary endpoint of a major clinical trial for a core product typically leads to significant valuation loss and loss of investor confidence.
-0.80Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit alleging Grail and its executives made false or misleading statements regarding the NHS-Galleri trial results. — Securities fraud litigation creates additional legal liabilities and overhangs the company's reputation and financial reserves.
-0.40Grail's stock price fell by more than 50% following the announcement of the failed trial endpoint. — While already reflected in the price, this confirms a massive destruction of shareholder value and high volatility.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is facing a class action lawsuit following a 50% stock price drop due to failed primary endpoints in a major clinical trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
